Your browser doesn't support javascript.
loading
The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease.
Noizat-Pirenne, F; Habibi, A; Mekontso-Dessap, A; Razazi, K; Chadebech, P; Mahevas, M; Vingert, B; Bierling, P; Galactéros, F; Bartolucci, P; Michel, M.
Affiliation
  • Noizat-Pirenne F; Établissement Français du Sang Ile de France, Créteil, France; INSERM U955, Equipe 2, UPEC, Créteil, France.
Vox Sang ; 108(3): 262-7, 2015 Apr.
Article in En | MEDLINE | ID: mdl-25523469
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Murine-Derived / Transfusion Reaction / Immunologic Factors / Anemia, Sickle Cell Type of study: Observational_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Vox Sang Year: 2015 Document type: Article Affiliation country: France Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Murine-Derived / Transfusion Reaction / Immunologic Factors / Anemia, Sickle Cell Type of study: Observational_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Vox Sang Year: 2015 Document type: Article Affiliation country: France Country of publication: United kingdom